Opportunity Information: Apply for PA 07 451
Apply for PA 07 451
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "New Technology for Proteomics and Glycomics (SBIR R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.837 Cardiovascular Diseases Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.859 Biomedical Research and Research Training.
- This funding opportunity was created on Jan 26, 2009 and posted on Sep 10, 2007.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses.
- Foreign institutions are not eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity titled "New Technology for Proteomics and Glycomics (SBIR R43/R44)" (Funding Opportunity Number PA-07-451) is aimed at small businesses that can build practical, broadly useful tools to move proteomics and glycomics forward. The central motivation is that many existing proteomics technologies are still not good enough for the kinds of measurements researchers increasingly need, especially when it comes to getting reliable quantitative results and making measurements in real time. In response, the FOA invites Small Business Innovation Research (SBIR) applications that focus on developing enabling technologies and methods that solve persistent, field-wide technical bottlenecks in how proteins and glycans are measured, characterized, and analyzed.
The scope is intentionally wide and covers most of the workflow from sample handling through data interpretation. On the front end, this includes robotics and automation, improved sample preparation, and pre-fractionation approaches that make complex biological samples easier to analyze. It also includes analytical separations (for example, better chromatography or electrophoresis strategies), gel and array imaging improvements, and stronger quantitation methods. A major area of interest is innovation around mass spectrometry, including better instrumentation components, workflows that improve sensitivity and throughput, and "intelligent" automated data acquisition strategies that can make experiments more efficient and reproducible. Just as important, the FOA highlights improved informatics technologies, recognizing that software, algorithms, and data systems are often the limiting factor in turning raw proteomics or glycomics data into interpretable biological conclusions. While the call is broadly applicable, it specifically emphasizes technologies that address the unique challenges of glycomics and clinical proteomics, which often involve additional complexity such as heterogeneous glycan structures and the need for robust performance in clinically relevant samples and settings.
From a funding mechanics standpoint, this announcement uses the SBIR grant mechanisms R43 (Phase I) and R44 (Phase II), and it accepts Phase I, Phase II, and Fast Track applications. In practice, that means a small business can propose an early feasibility and proof-of-concept effort under Phase I, then propose a more advanced development and validation effort under Phase II, or use the Fast Track option to link the two phases in a single, continuous plan. The FOA runs in parallel with an STTR companion announcement (PA-07-452) that has the same scientific scope but uses the STTR mechanisms (R41/R42), which is relevant for teams deciding whether their commercialization and collaboration structure fits better under SBIR or STTR rules.
The budget guidance is clear and fairly generous for technology development. For Phase I, applicants may request up to $200,000 in total costs per year for project periods up to 2 years. For Phase II, applicants may request up to $400,000 in total costs per year for project periods up to 4 years. As with most federal grant programs, the announcement notes that awards depend on the availability of funds and on receiving enough highly meritorious applications, so meeting the technical goals and presenting a strong development plan are essential.
Eligibility is limited to small business concerns as defined by the SBIR program, and foreign institutions are not eligible to apply. There is no cost sharing or matching requirement. The opportunity is categorized as a discretionary grant in the health area, administered by the National Institutes of Health, and it was originally posted on September 10, 2007, with multiple receipt dates rather than a single deadline. The full announcement is hosted through the NIH grants guide (linked in the source text), and NIH provides support contacts through the Office of Extramural Research for access or linking issues.
Overall, this FOA is best read as a targeted push for small businesses to create the next generation of practical proteomics and glycomics tools: technologies that reduce friction across the experimental pipeline, improve quantitative and real-time measurement capabilities, increase automation and throughput, and strengthen the computational backbone needed to handle complex datasets, with particular interest in solutions that can succeed in glycomics and clinical proteomics use cases.
Frequently Asked Questions (FAQs): New Technology for Proteomics and Glycomics (SBIR R43/R44) - PA-07-451
What is the title and funding opportunity number (FON) for this NIH program?
The program is titled "New Technology for Proteomics and Glycomics (SBIR R43/R44)" and the Funding Opportunity Number is PA-07-451.
What is the main goal of this funding opportunity?
The main goal is to support small businesses in developing practical, broadly useful enabling technologies and methods that move proteomics and glycomics forward by solving persistent, field-wide technical bottlenecks in how proteins and glycans are measured, characterized, and analyzed.
Why is NIH issuing this call for new technology?
The central motivation is that many existing proteomics technologies are not sufficient for newer research needs, especially for reliable quantitative measurements and making measurements in real time. This FOA seeks technology advances that improve performance, efficiency, and reproducibility across proteomics and glycomics workflows.
Who is eligible to apply?
Eligibility is limited to small business concerns as defined by the SBIR program. Foreign institutions are not eligible to apply.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What NIH funding mechanisms are used in this opportunity?
This announcement uses SBIR grant mechanisms R43 (Phase I) and R44 (Phase II).
What application types are accepted (Phase I, Phase II, Fast Track)?
The FOA accepts Phase I, Phase II, and Fast Track applications. Phase I typically supports early feasibility and proof-of-concept, Phase II supports more advanced development and validation, and Fast Track links Phase I and Phase II into a single, continuous plan.
How much funding can be requested for Phase I?
For Phase I, applicants may request up to $200,000 in total costs per year, for project periods up to 2 years.
How much funding can be requested for Phase II?
For Phase II, applicants may request up to $400,000 in total costs per year, for project periods up to 4 years.
Are awards guaranteed if an application is submitted?
No. The FOA notes that awards depend on the availability of funds and on receiving enough highly meritorious applications.
What kinds of technologies are within scope?
The scope is intentionally wide and spans much of the workflow from sample handling through data interpretation. The FOA is aimed at enabling technologies that address technical bottlenecks in proteomics and glycomics measurement and analysis.
Does the FOA include sample handling and preparation technologies?
Yes. The front end of the workflow includes robotics and automation, improved sample preparation, and pre-fractionation approaches that help make complex biological samples easier to analyze.
Are analytical separations and imaging improvements included?
Yes. The FOA includes analytical separations (such as improved chromatography or electrophoresis strategies), gel and array imaging improvements, and stronger quantitation methods.
Is mass spectrometry innovation specifically encouraged?
Yes. A major area of interest is innovation around mass spectrometry, including better instrumentation components, workflows that improve sensitivity and throughput, and intelligent automated data acquisition strategies designed to make experiments more efficient and reproducible.
Are software and informatics tools considered responsive to this FOA?
Yes. The FOA explicitly highlights improved informatics technologies, recognizing that software, algorithms, and data systems can be limiting factors in turning raw proteomics or glycomics data into interpretable biological conclusions.
Does this opportunity support technology that improves quantitative or real-time measurements?
Yes. The FOA is motivated in part by the need for better reliable quantitative results and the ability to make measurements in real time, and it invites technologies that improve these capabilities.
Is there a particular emphasis on glycomics challenges?
Yes. While broadly applicable, the FOA specifically emphasizes technologies that address unique challenges of glycomics, including complexities associated with heterogeneous glycan structures.
Is there a particular emphasis on clinical proteomics?
Yes. The FOA specifically emphasizes technologies that address challenges in clinical proteomics, including the need for robust performance in clinically relevant samples and settings.
Does the announcement cover the full experimental pipeline?
Yes. It covers most of the workflow, from sample handling and preparation, through separations and measurement technologies, to downstream informatics and data interpretation.
Is there a related STTR opportunity with the same scope?
Yes. This SBIR FOA runs in parallel with an STTR companion announcement, PA-07-452, which has the same scientific scope but uses STTR mechanisms (R41/R42).
How does the STTR companion announcement relate to this SBIR FOA?
The STTR companion (PA-07-452) is relevant for teams deciding whether their commercialization and collaboration structure fits better under SBIR rules (R43/R44) or STTR rules (R41/R42), while targeting the same scientific and technical scope.
What agency administers this funding opportunity?
The opportunity is administered by the National Institutes of Health (NIH).
What type of grant program category is this?
It is categorized as a discretionary grant in the health area.
When was this FOA originally posted?
It was originally posted on September 10, 2007.
Is there a single deadline or multiple receipt dates?
The FOA has multiple receipt dates rather than a single deadline.
Where can applicants find the full official announcement?
The full announcement is hosted through the NIH grants guide, as referenced in the source information.
Who should be contacted for access or linking issues related to the NIH posting?
NIH provides support contacts through the Office of Extramural Research for access or linking issues.
What is NIH looking for in terms of impact and usefulness?
NIH is looking for practical, broadly useful tools that reduce friction across the experimental pipeline, improve automation and throughput, strengthen quantitative and real-time measurement capabilities, and improve reproducibility and interpretability of proteomics and glycomics results.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: New Technology for Proteomics and Glycomics (STTR R41/R42)
Previous opportunity: Bioengineering Approaches to Energy Balance and Obesity (STTR R41/R42)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 07 451
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 07 451) also looked into and applied for these:
| Funding Opportunity |
|---|
| New Technology for Proteomics and Glycomics (STTR R41/R42) Apply for PA 07 452 Funding Number: PA 07 452 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| High Throughput Tools for Brain and Behavior (SBIR R43/R44) Apply for PA 08 001 Funding Number: PA 08 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| High Throughput Tools for Brain and Behavior (STTR R41/R42) Apply for PA 08 002 Funding Number: PA 08 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of PET and SPECT Ligands for Brain Imaging (SBIR R43/R44) Apply for PA 08 137 Funding Number: PA 08 137 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pharmacologic Agents and Drugs for Mental Disorders (SBIR R43/R44) Apply for PA 08 142 Funding Number: PA 08 142 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Cooperative Program in Translational Research Small Business Awards (SBIR U44) Apply for PAR 08 235 Funding Number: PAR 08 235 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| State Implementation Grants for Integrated Community Systems for CSHCN Apply for HRSA 09 159 Funding Number: HRSA 09 159 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| Part D Coordinated HIV Services and Access to Research for WICY One TimeSupplemental Funds Apply for HRSA 09 143 Funding Number: HRSA 09 143 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Development, Implementation and Evaluation of Strategies to Increase Vaccination of Adolescents Affiliated with a Medical Home (U01) Apply for RFA IP 09 006 Funding Number: RFA IP 09 006 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $550,000 |
| Evaluation of New Technology to Improve Delivery of Immunizations (U01) Apply for RFA IP 09 005 Funding Number: RFA IP 09 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $225,000 |
| NCMHD Endowment Program for Increasing Research and Institutional Resources Capacity in Section 736 Health Professions Schools (NCMHD Research Endowment Fund) (S21) Apply for RFA MD 09 002 Funding Number: RFA MD 09 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Extension of the World Trade Center Registry (U50) Apply for RFA OH 09 002 Funding Number: RFA OH 09 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $12,000,000 |
| NCMHD Research Infrastructure in Minority Institutions (P20) Apply for RFA MD 09 003 Funding Number: RFA MD 09 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Community Based HIV/AIDS Prevention, Care and Support Apply for USAID UGANDA RFA 617 09 005 Funding Number: USAID UGANDA RFA 617 09 005 Agency: Agency for International Development Category: Health Funding Amount: $22,000,000 |
| Pre Application for Dietary Supplement Research Centers Botanicals (X02) Apply for PAR 09 091 Funding Number: PAR 09 091 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| SECURING UGANDAS RIGHT TO ESSENTIAL MEDICINE Apply for USAID UGANDA RFA 617 09 001 Funding Number: USAID UGANDA RFA 617 09 001 Agency: Agency for International Development Category: Health Funding Amount: $40,000,000 |
| NHLBI Progenitor Cell Biology Consortium Research Hubs (U01) Apply for RFA HL 09 004 Funding Number: RFA HL 09 004 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| NHLBI Progenitor Cell Biology Consortium Administrative Coordinating Center (U01) Apply for RFA HL 09 005 Funding Number: RFA HL 09 005 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Strengthening National Capacity in Malaria and Other Infectious Disease Operations Research (U01) Apply for RFA CK 09 004 Funding Number: RFA CK 09 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $650,000 |
| Translational Tools for Clinical Studies of CAM Interventions (R01) Apply for RFA AT 09 002 Funding Number: RFA AT 09 002 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 451", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.